002399.SHE Shenzhen Hepalink Pharmaceutical Co Ltd
- Market cap
- CNY 13.5B
- P/E
- 70.9x
- P/B
- 1.12x
- ROE
- 4.4%
- Dividend yield
- 3.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002399.SHE undervalued?
Graham number002399.SHE trades 88.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Hepalink Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shenzhen Hepalink Pharmaceutical Co Ltd yet.
Shenzhen Hepalink Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium…
Full company profileShenzhen Hepalink Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Hepalink Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.26B | 2.84B | 4.81B | 4.62B | 5.33B | 6.37B | 7.16B | 5.43B | 5.26B | 5.48B | 5.06B |
| Gross Profit | 698M | 863M | 1.88B | 1.68B | 2.03B | 2.00B | 2.30B | 941M | 1.74B | 1.74B | 1.74B |
| Operating Income | 436M | 92.2M | 692M | 1.31B | 1.33B | 227M | 829M | -434M | 507M | 636M | 646M |
| EBITDA | 743M | 472M | 1.15B | 1.85B | 1.88B | 694M | 1.36B | -367M | 1.16B | 847M | 594M |
| Net Income | 397M | 197M | 591M | 1.06B | 1.02B | 241M | 727M | -783M | 647M | 349M | 525M |
| EPS | 0.32 | 0.16 | 0.47 | 0.85 | 0.76 | 0.16 | 0.50 | -0.53 | 0.44 | 0.24 | 0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 12.9B | 13.2B | 13.7B | 15.2B | 19.0B | 19.1B | 20.8B | 19.2B | 17.3B | 16.6B | 16.6B |
| Total Liabilities | 4.83B | 5.50B | 7.41B | 7.77B | 7.34B | 7.58B | 8.41B | 7.22B | 5.14B | 4.55B | 4.52B |
| Shareholders' Equity | 7.97B | 7.58B | 6.07B | 7.35B | 11.6B | 11.4B | 12.3B | 11.9B | 12.1B | 12.0B | 12.0B |
| Cash & Short-term Investments | 4.56B | 3.50B | 2.20B | 1.39B | 3.54B | 3.93B | 3.45B | 2.27B | 2.56B | 1.35B | 1.46B |
| Total Debt | 3.89B | 4.71B | 4.92B | 6.30B | 5.65B | 5.65B | 6.46B | 5.56B | 2.98B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 346M | -407M | 668M | -228M | 37.3M | -6.63M | -757M | 398M | 2.19B | 1.71B | - |
| Capital Expenditure | 360M | 576M | 535M | 362M | 212M | 194M | 222M | 445M | 203M | 121M | 105M |
| Free Cash Flow | -13.5M | -983M | 133M | -590M | -175M | -200M | -979M | -46.7M | 1.99B | 1.59B | 1.90B |
| Ratios | |||||||||||
| ROE | 5.0% | 2.6% | 9.7% | 14.4% | 8.9% | 2.1% | 5.9% | -6.6% | 5.3% | 2.9% | 4.4% |
| ROA | 3.1% | 1.5% | 4.3% | 7.0% | 5.4% | 1.3% | 3.5% | -4.1% | 3.7% | 2.1% | 3.2% |
| Net Profit Margin | 17.6% | 6.9% | 12.3% | 22.9% | 19.2% | 3.8% | 10.2% | -14.4% | 12.3% | 6.4% | 10.4% |
| Debt to Equity | 0.49x | 0.62x | 0.81x | 0.86x | 0.49x | 0.50x | 0.53x | 0.47x | 0.25x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Hepalink Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.18%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 123.3%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 431M | 0.29 | 123.3% |
| 2024 | CNY 160M | 0.11 | 24.7% |
| 2023 | CNY 426M | 0.29 | - |
| 2022 | CNY 51.4M | 0.03 | 7.1% |
| 2021 | CNY 220M | 0.15 | 91.4% |
| 2020 | CNY 224M | 0.17 | 21.9% |
| 2019 | CNY 343M | 0.27 | 32.3% |
| 2018 | CNY 255M | 0.20 | 43.1% |
| 2017 | CNY 445M | 0.36 | 226.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 16:10 on Jun 13, 2016.
Who owns Shenzhen Hepalink Pharmaceutical Co Ltd
- Insiders 82.42%
- Institutions 0.57%
- Public & others 17.01%
- Shares outstanding 1.25B
- Free float 404M
Shenzhen Hepalink Pharmaceutical Co Ltd company profile
- Company name
- Shenzhen Hepalink Pharmaceutical Co Ltd
- Ticker
- 002399.SHE
- ISIN
- CNE100000P02
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,150
- Fiscal year end
- December
- Address
- No. 21 Langshan Road, Shenzhen, China, 518057
- Phone
- 86 755 2698 0200
- Website
- hepalink.com
About Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Shenzhen Hepalink Pharmaceutical Co Ltd management
7- Mr. Li LiCo-Founder, Executive Chairman of the Board & President · born 1964
- Mr. Yu ShanCo-Founder, GM, Group VP & Executive Director · born 1960
- Ms. Tan LiCo-founder, VP, Deputy GM & Executive Director · born 1964
- Ms. Juan ChenVP of Finance, CFO & Financial Controller · born 1975
- Mr. Jianyi WangEmployee Representative Director & Director of Organization and HR · born 1982
- Mr. Xi GaoSenior Vice President of Global Supply Chain
- Mr. Fengqi QianCompany Secretary · born 1985